Drug Profile
Phorbol esters - HypGen
Latest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Mega Bridge
- Developer HypGen; Rich Pharmaceuticals
- Class Antiparkinsonians; Phorbol esters
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease; Stroke
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for phase-I development in Parkinson's-disease in USA (Parenteral)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Stroke in USA (Parenteral)
- 24 Jul 2019 Phase-I clinical trials in Parkinson's disease in USA (Parenteral) (HypGen pipeline, July 2019)